GGHC
OREX

Gilder Gagnon Howe & Co’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,253
Closed -$176K – 312
2015
Q1 		$176K Buy
+2,253
New +$140K ﹤0.01% 237

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Gilder Gagnon Howe & Co's OREX Position: Q2 2015 in Review

Gilder Gagnon Howe & Co sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2015, closing a stake of 2,253 shares — an estimated $176K sold.

Gilder Gagnon Howe & Co first reported a position in OREX in Q1 2015 and held it in 1 quarter. The position peaked at $176K in Q1 2015. 161 funds tracked by Wall St. Rank hold OREX as of Q2 2015.

  • Gilder Gagnon Howe & Co reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 2,253 Orexigen Therapeutics, Inc. shares in Q2 2015, an estimated $176K.
  • Gilder Gagnon Howe & Co first reported a position in Orexigen Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Orexigen Therapeutics, Inc. position peaked at $176K in Q1 2015.
  • 161 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2015.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2015, filed 30 Jul 2015.